Keros Therapeutics’ (KROS) “Neutral” Rating Reaffirmed at Wedbush

Wedbush reissued their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Tuesday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Several other research firms have also recently weighed in on KROS. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Oppenheimer dropped their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research note on Thursday, January 16th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday. Finally, Scotiabank lowered their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Down 6.3 %

NASDAQ KROS opened at $9.55 on Tuesday. The firm has a market capitalization of $387.37 million, a PE ratio of -1.83 and a beta of 1.39. The business’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $33.64. Keros Therapeutics has a 12 month low of $9.41 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. As a group, analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. AlphaQuest LLC grew its position in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after purchasing an additional 2,964 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its holdings in Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after buying an additional 1,033 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after buying an additional 1,998 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Keros Therapeutics by 59.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after buying an additional 1,994 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics during the fourth quarter worth about $90,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.